EMA AMENDS MARKET APPROVAL RULES BASED ON PHARMACOVIGILANCE EXPERIENCE
March 1st, 2014FRESH changes have been made by the European Medicines Authority (EMA) to its market authorisation procedures based on experience gained from the implementation of new European Union (EU) pharmacovigilance rules. The reforms cover, for instance, the submission of paediatric medicine studies, environmental risk assessments and amendments of deadlines for delivering marketing authorisation conditions. *http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2013/07/WC500146564.pdf
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.